![Benzo[d]thiazol-2-amine](/upload/1124/V62014.png)
| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Not applicable (chemical intermediate). Benzo[d]thiazol-2-amine is a chemical intermediate used in organic synthesis and pharmaceutical manufacturing. It does not have a defined pharmacological target.
|
|---|---|
| ln Vitro |
Benzo[d]thiazol-2-amine is a chemical intermediate and ligand used in organic synthesis. It does not exhibit direct pharmacological activity in standard in vitro assays. It is used to synthesize pharmaceutical compounds such as pramipexole.
|
| ln Vivo |
In vivo studies of benzo[d]thiazol-2-amine are not applicable as the compound is a chemical intermediate rather than a pharmacologically active compound.
|
| Enzyme Assay |
Non-cell-based assays for benzo[d]thiazol-2-amine are analytical in nature. Standard methods including HPLC, NMR, and mass spectrometry are used for identification, quantification, and purity assessment. Physicochemical properties such as melting point are determined using standard protocols.
|
| Cell Assay |
Cell-based assays for benzo[d]thiazol-2-amine are not commonly performed, as the compound is a chemical intermediate rather than a pharmacologically active compound.
|
| Animal Protocol |
In vivo animal studies for benzo[d]thiazol-2-amine are not applicable as the compound is a chemical intermediate.
|
| ADME/Pharmacokinetics |
Benzo[d]thiazol-2-amine has a molecular formula of C₇H₆N₂S and a molecular weight of 150.20 g/mol. It is an odorless gray to white powder with a melting point of 126-129°C. It is used as an organic synthesis intermediate and pharmaceutical intermediate for drugs such as pramipexole and as a ligand for dinuclear complexes.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for benzo[d]thiazol-2-amine are limited. Standard laboratory safety practices should be followed when handling this compound.
|
| References | |
| Additional Infomation |
2-Aminobenzothiazole is an odorless, grayish-white powder. (NTP, 1992)
2-Aminobenzothiazole is a type of benzothiazole compound. Benzo[d]thiazol-2-amine (2-Aminobenzothiazole) is a heterocyclic compound used as an organic synthesis intermediate and pharmaceutical intermediate for the synthesis of various drugs such as pramipexole. It is also a favorable ligand for the synthesis of dinuclear complexes containing nitrogen heterocycles. It is for research use only. |
| Molecular Formula |
C7H6N2S
|
|---|---|
| Molecular Weight |
150.20
|
| Exact Mass |
150.025
|
| CAS # |
136-95-8
|
| PubChem CID |
8706
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
307.5±25.0 °C at 760 mmHg
|
| Melting Point |
270 °F (NTP, 1992)
; 132 °C
|
| Flash Point |
139.8±23.2 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.763
|
| LogP |
1.89
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
10
|
| Complexity |
129
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)N=C(S2)N
|
| InChi Key |
UHGULLIUJBCTEF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H6N2S/c8-7-9-5-3-1-2-4-6(5)10-7/h1-4H,(H2,8,9)
|
| Chemical Name |
1,3-benzothiazol-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (665.78 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (16.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (16.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (16.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.6578 mL | 33.2889 mL | 66.5779 mL | |
| 5 mM | 1.3316 mL | 6.6578 mL | 13.3156 mL | |
| 10 mM | 0.6658 mL | 3.3289 mL | 6.6578 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT00865475
Conditions:HIV Infection|HIV InfectionsLink: https://clinicaltrials.gov/ct2/show/NCT00335192
Conditions:HIVProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
